A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc)

被引：0
|
作者：
Davelaar, John
Tighiouart, Mourad
Hendifar, Andrew Eugene
Osipov, Arsen
Moshayedi, Natalie
Placencio-Hickok, Veronica
Bhowmick, Neil
Gong, Jun
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS636
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naive Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
    Gong, Jun
    Osipov, Arsen
    Lorber, Jeremy
    Tighiouart, Mourad
    Kwan, Albert K.
    Muranaka, Hayato
    Akinsola, Rasaq
    Billet, Sandrine
    Levi, Abrahm
    Abbas, Anser
    Davelaar, John
    Bhowmick, Neil
    Hendifar, Andrew E.
    BIOMEDICINES, 2023, 11 (05)
  • [2] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
    Safran, Howard
    Perez, Kimberly
    Charpentier, Kevin
    Austin, Trevor Clark
    Mantripragada, Kalyan C.
    Bishop, Kenneth D.
    Lombardo, Alise
    Houlihan, Lindsay
    Mitchell, Kristen
    Rosati, Kayla
    Martel, Diane
    Shaw, Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
    De Vita, Fernando
    Orditura, Michele
    Febbraro, Antonio
    Morgillo, Floriana
    Laterza, Maria Maddalena
    Fabozzl, Alesslo
    Giordano, Guido
    Savastano, Beatrice
    Petrillo, Angelica
    Ventriglia, Joie
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
    Ernani, Vinicius
    Akunyili, Ikechukwu Immanuel
    Hosein, Peter Joel
    Macintyre, Jessica
    Lima, Caio Max S. Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [10] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345